|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valentini V and Cellini F: Radiotherapy in
gastric cancer: A systematic review of literature and new
perspectives. Expert Rev Anticancer Ther. 7:1379–1393. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perez EA and Spano JP: Current and
emerging targeted therapies for metastatic breast cancer. Cancer.
118:3014–3025. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
No M, Choi EJ and Kim IA: Targeting HER2
signaling pathway for radiosensitization: Alternative strategy for
therapeutic resistance. Cancer Biol Ther. 8:2351–2361. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hou J, Zhou Z, Chen X, Zhao R, Yang Z, Wei
N, Ni Q, Feng Y, Yu X, Ma J and Guo X: HER2 reduces breast cancer
radiosensitivity by activating focal adhesion kinase in vitro and
in vivo. Oncotarget. 7:45186–45198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu T, Cho BJ, Choi EJ, Park JM, Kim DH and
Kim IA: Radiosensitizing effect of lapatinib in human epidermal
growth factor receptor 2-positive breast cancer cells. Oncotarget.
7:79089–79100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL,
Cheng AL, Pu YS and Cheng JC: Synergistic blockade of EGFR and HER2
by new-generation EGFR tyrosine kinase inhibitor enhances radiation
effect in bladder cancer cells. Mol Cancer Ther. 14:810–820. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang K, Lu Y, Jin W, Ang KK, Milas L and
Fan Z: Sensitization of breast cancer cells to radiation by
trastuzumab. Mol Cancer Ther. 2:1113–1120. 2003.PubMed/NCBI
|
|
12
|
Jacob J, Belin L, Pierga JY, Gobillion A,
Vincent-Salomon A, Dendale R, Beuzeboc P, Campana F, Fourquet A and
Kirova YM: Concurrent administration of trastuzumab with
locoregional breast radiotherapy: Long-term results of a
prospective study. Breast Cancer Res Treat. 148:345–353. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Yu S, Zhuang L, Zheng Z, Chao T
and Fu Q: Caveolin-1 is involved in radiation-induced ERBB2 nuclear
transport in breast cancer cells. J Huazhong Univ Sci Technolog Med
Sci. 32:888–892. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo B, Yu S, Zhuang L, Xia S, Zhao Z and
Rong L: Induction of ERBB2 nuclear transport after radiation in
breast cancer cells. J Huazhong Univ Sci Technolog Med Sci.
29:350–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valabrega G, Montemurro F and Aglietta M:
Trastuzumab: Mechanism of action, resistance and future
perspectives in HER2-overexpressing breast cancer. Ann Oncol.
18:977–984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi H, Zhang W, Zhi Q and Jiang M:
Lapatinib resistance in HER2+ cancers: Latest findings
and new concepts on molecular mechanisms. Tumour Biol. Oct
10–2016.(Epub ahead of print). doi: 10.1007/s13277-016-5467-2.
View Article : Google Scholar
|
|
17
|
Canonici A, Gijsen M, Mullooly M, Bennett
R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E,
et al: Neratinib overcomes trastuzumab resistance in HER2 amplified
breast cancer. Oncotarget. 4:1592–1605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu Y, Li L, Zhang G, Wan H, Yang C, Diao
X, Chen X, Zhang L and Zhong D: Metabolic characterization of
pyrotinib in humans by ultra-performance liquid
chromatography/quadrupole time-of-flight mass spectrometry. J
Chromatogr B Analyt Technol Biomed Life Sci. 1033-1034:117–127.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sartor CI: Epidermal growth factor family
receptors and inhibitors: Radiation response modulators. Semin
Radiat Oncol. 13:22–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Yang C, Wan H, Zhang G, Feng J and
Zhang L, Chen X, Zhong D, Lou L, Tao W and Zhang L: Discovery and
development of pyrotinib: A novel irreversible EGFR/HER2 dual
tyrosine kinase inhibitor with favorable safety profiles for the
treatment of breast cancer. Eur J Pharm Sci. 110:51–61. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khanna KK and Jackson SP: DNA
double-strand breaks: Signaling, repair and the cancer connection.
Nat Genet. 27:247–254. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cordo Russo RI, Béguelin W, Díaz Flaqué
MC, Proietti CJ, Venturutti L, Galigniana N, Tkach M, Guzmán P, Roa
JC, O'Brien NA, et al: Targeting ErbB-2 nuclear localization and
function inhibits breast cancer growth and overcomes trastuzumab
resistance. Oncogene. 34:3413–3428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schillaci R, Guzmán P, Cayrol F, Beguelin
W, Diaz Flaque MC, Proietti CJ, Pineda V, Palazzi J, Frahm I,
Charreau EH, et al: Clinical relevance of ErbB-2/HER2 nuclear
expression in breast cancer. BMC Cancer. 12:742012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang SM and Harari PM: Modulation of
radiation response after epidermal growth factor receptor blockade
in squamous cell carcinomas: Inhibition of damage repair, cell
cycle kinetics, and tumor angiogenesis. Clin Cancer Res.
6:2166–2174. 2000.PubMed/NCBI
|
|
25
|
Ethier SP and Lawrence TS: Epidermal
growth factor receptor signaling and response of cancer cells to
ionizing radiation. J Natl Cancer Inst. 93:890–891. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dent P, Yacoub A, Contessa J, Caron R,
Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R:
Stress and radiation-induced activation of multiple intracellular
signaling pathways. Radiat Res. 159:283–300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Halyard MY, Pisansky TM, Dueck AC, Suman
V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, et
al: Radiotherapy and adjuvant trastuzumab in operable breast
cancer: Tolerability and adverse event data from the NCCTG Phase
III Trial N9831. J Clin Oncol. 27:2638–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Belkacémi Y, Gligorov J, Ozsahin M,
Marsiglia H, De Lafontan B, Laharie-Mineur H, Aimard L, Antoine EC,
Cutuli B, Namer M and Azria D: Concurrent trastuzumab with adjuvant
radiotherapy in HER2-positive breast cancer patients: Acute
toxicity analyses from the French multicentric study. Ann Oncol.
19:1110–1116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Horton JK, Halle J, Ferraro M, Carey L,
Moore DT, Ollila D and Sartor CI: Radiosensitization of
chemotherapy-refractory, locally advanced or locally recurrent
breast cancer with trastuzumab: A phase II trial. Int J Radiat
Oncol Biol Phys. 76:998–1004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Contessa JN, Hampton J, Lammering G,
Mikkelsen RB, Dent P, Valerie K and Schmidt-Ullrich RK: Ionizing
radiation activates Erb-B receptor dependent Akt and p70 S6 kinase
signaling in carcinoma cells. Oncogene. 21:4032–4041. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bowers G, Reardon D, Hewitt T, Dent P,
Mikkelsen RB, Valerie K, Lammering G, Amir C and Schmidt-Ullrich
RK: The relative role of ErbB1-4 receptor tyrosine kinases in
radiation signal transduction responses of human carcinoma cells.
Oncogene. 20:1388–1397. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trip AK, Poppema BJ, van Berge Henegouwen
MI, Siemerink E, Beukema JC, Verheij M, Plukker JT, Richel DJ,
Hulshof MC, van Sandick JW, et al: Preoperative chemoradiotherapy
in locally advanced gastric cancer, a phase I/II feasibility and
efficacy study. Radiother Oncol. 112:284–288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ajani JA, Winter K, Okawara GS, Donohue
JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD,
Willett C and Rich TA: Phase II trial of preoperative
chemoradiation in patients with localized gastric adenocarcinoma
(RTOG 9904): Quality of combined modality therapy and pathologic
response. J Clin Oncol. 24:3953–3958. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ajani JA, Mansfield PF, Janjan N, Morris
J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS and
Gunderson LL: Multi-institutional trial of preoperative
chemoradiotherapy in patients with potentially resectable gastric
carcinoma. J Clin Oncol. 22:2774–2780. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Newton AD, Datta J, Loaiza-Bonilla A,
Karakousis GC and Roses RE: Neoadjuvant therapy for gastric cancer:
Current evidence and future directions. J Gastrointest Oncol.
6:534–543. 2015.PubMed/NCBI
|
|
37
|
Smalley SR, Benedetti JK, Haller DG,
Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson
JA, Jessup JM, et al: Updated analysis of SWOG-directed intergroup
study 0116: A phase III trial of adjuvant radiochemotherapy versus
observation after curative gastric cancer resection. J Clin Oncol.
30:2327–2333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park SH, Sohn TS, Lee J, Lim DH, Hong ME,
Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, et al: Phase III trial to
compare adjuvant chemotherapy with capecitabine and cisplatin
versus concurrent chemoradiotherapy in gastric cancer: Final report
of the adjuvant chemoradiotherapy in stomach tumors trial,
including survival and subset analyses. J Clin Oncol. 33:3130–3136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fisher B, Anderson S, Bryant J, Margolese
RG, Deutsch M, Fisher ER, Jeong JH and Wolmark N: Twenty-year
follow-up of a randomized trial comparing total mastectomy,
lumpectomy, and lumpectomy plus irradiation for the treatment of
invasive breast cancer. N Engl J Med. 347:1233–1241. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clarke M, Collins R, Darby S, Davies C,
Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al:
Effects of radiotherapy and of differences in the extent of surgery
for early breast cancer on local recurrence and 15-year survival:
An overview of the randomised trials. Lancet. 366:2087–2106. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), ; Darby S, McGale P, Correa C, Taylor
C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J,
et al: Effect of radiotherapy after breast-conserving surgery on
10-year recurrence and 15-year breast cancer death: Meta-analysis
of individual patient data for 10,801 women in 17 randomised
trials. Lancet. 378:1707–1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Van de Steene J, Soete G and Storme G:
Adjuvant radiotherapy for breast cancer significantly improves
overall survival: The missing link. Radiother Oncol. 55:263–272.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ragaz J, Olivotto IA, Spinelli JJ,
Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L,
Gelmon K, et al: Locoregional radiation therapy in patients with
high-risk breast cancer receiving adjuvant chemotherapy: 20-year
results of the British Columbia randomized trial. J Natl Cancer
Inst. 97:116–126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J,
Luo Y, Xing P, Lan B, Li M, et al: Phase I study and biomarker
analysis of pyrotinib, a novel irreversible Pan-ErbB receptor
tyrosine kinase inhibitor, in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer. J Clin Oncol.
35:3105–3112. 2017. View Article : Google Scholar : PubMed/NCBI
|
